1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial

We sought to assess the safety and efficacy of the novel VESTAsync-eluting stent (MIV Therapeutics, Atlanta, Georgia) combining a stainless steel platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free low-dose of sirolimus (55 microg). Durable polymers in...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Cardiovascular interventions 2009-05, Vol.2 (5), p.422-427
Main Authors: Costa, Jr, J Ribamar, Abizaid, Alexandre, Costa, Ricardo, Feres, Fausto, Tanajura, Luiz Fernando, Abizaid, Andréa, Maldonado, Galo, Staico, Rodolfo, Siqueira, Dimytri, Sousa, Amanda G M R, Bonan, Raoul, Sousa, J Eduardo
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary
Aspirin
Coronary Angiography
Coronary Artery Bypass
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - drug therapy
Coronary Artery Disease - therapy
Coronary Restenosis
Drug-Eluting Stents
Durapatite
Female
Humans
Intensive Care Units
Male
Middle Aged
Platelet Aggregation Inhibitors - therapeutic use
Polymers
Prospective Studies
Sirolimus - administration & dosage
Sirolimus - therapeutic use
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Time Factors
Ultrasonography
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We sought to assess the safety and efficacy of the novel VESTAsync-eluting stent (MIV Therapeutics, Atlanta, Georgia) combining a stainless steel platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free low-dose of sirolimus (55 microg). Durable polymers in first-generation drug-eluting stents (DES) have been linked to local inflammatory reaction leading to a positive vessel remodeling, late incomplete stent apposition, and in some cases, stent thrombosis. The removal of the polymer from the DES system could increase the safety profile of this novel technology. A total of 15 patients with single de novo lesions in native coronary arteries with 3.0- to 3.5-mm diameter and
ISSN:1876-7605
DOI:10.1016/j.jcin.2009.02.009